Core
Apr 11, 2026
Plus, a precision oncology biotech with room to run, a CNS drug challenger with nearly $4B in projected peak sales, and more...
Apr 4, 2026
Plus, a top-1% analyst's highest-conviction AI infrastructure bet and the post-IPO software name Goldman says the market is missing out on.
Apr 1, 2026
The market may be missing a protein upgrade that favors eggs.
Mar 28, 2026
Plus, a firm with three hyperscale leases signed, a biotech with four drugs on market, and a stock down 29% that activists just shook up.
Not a Member Yet?
Enter your email below to unlock exclusive discounts on the next page
90-Day Money-Back Guarantee
